5-Fluorouracil and Interferon-α in chemotherapy refractory bladder carcinoma: An effective regimen

C. J. Logothetis, E. Hossan, G. Recondo, A. Sella, J. Ellerhorst, R. Kilbourn, A. Zukiwski, R. Amato

نتاج البحث: نشر في مجلةمقالةمراجعة النظراء

15 اقتباسات (Scopus)

ملخص

Seventy-seven patients with metastatic transitional cell carcinoma of the bladder who were unable to receive primary Cisplatin-based therapy or failed primary chemotherapy received one of three sequential 5-Fluorouracil-based salvage regimens: a) 5-Fluorouracil (1000 mg/m2 B.S.A. x 5 days) and Mitomycin-C (14 mg/m2 B.S.A. 6 week intervals), b) 5-Fluorouracil (750 mg/m2 B.S.A. x 5 days) and a-Interferon (5 miu/m2 B.S.A. daily x 5 then 3 times a week (TIW), c) 5-Fluorouracil (500 mg/m2 B.S.A. x 5 days), a-Interferon (5 miu/m2 B.S.A. x 5 days then TIW) and 13-Cis Retinoic Acid in escalating doses daily. Only 1 (6%) of the patients with regimen A responded, whereas 9 (30%) of the patients with regimen B and 8 (27%) in regimen C responded. Although all responses were partial remissions, responses were seen in patients with advanced and initially refractory transitional cell carcinomas. This data reveals that a-Interferon and 5-Fluorouracil is an effective combination in the treatment of metastatic transitional cell carcinoma and worthy of further study.

اللغة الأصليةالإنجليزيّة
الصفحات (من إلى)1265-1269
عدد الصفحات5
دوريةAnticancer Research
مستوى الصوت14
رقم الإصدار3 B
حالة النشرنُشِر - 1994
منشور خارجيًانعم

بصمة

أدرس بدقة موضوعات البحث “5-Fluorouracil and Interferon-α in chemotherapy refractory bladder carcinoma: An effective regimen'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا